Table 79Summary clinical evidence profile, comparison 8: GnRH agonist + placebo versus progestin + placebo

OutcomesIllustrative comparative risks (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)Comments
Assumed riskCorresponding risk
MPA and placebo nasal sprayGnRH agonist (nafarelin) IN + placebo tablets
Paid working life Nottingham Health Profile Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate an improvement in the nafarelin group, but not in the MPA group (p=0.06)
Household work Nottingham Health Profile Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in household work score (data not shown)
Vacation life Nottingham Health Profile Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in vacation life score (p=0.72)
Leisure Nottingham Health Profile Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in leisure score (p=0.93)
Sexual life Nottingham Health Profile Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in sexual life score (p=0.90)
Disturbed sleep Goldberg’s General Health Q Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in sleep disturbance (difficulties of falling asleep, early wakening and nightmares) score (p=0.19)
Anxiety-depression Goldberg’s General Health Q Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in anxietydepression score (p=0.20)
Motivation coping wheel, ISSI and demands, control and support Q Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in motivation score (p=0.41)
Emotional balance Coping wheel, ISSI and demands, control and support Q Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in emotional balance score (p=0.44)
Structure Coping wheel, ISSI and demands, control and support Q Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in structure score (p=0.41)
Coping Coping wheel, ISSI and demands, control and support Q Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in coping score (p=0.39)
Psychological work demands Coping wheel, ISSI and demands, control and support Q Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in ‘psychological work demands’ score (p=0.51)
Intellectual discretion at work Coping wheel, ISSI and demands, control and support Q Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in ‘intellectual discretion at work’ score (p=0.95)
Authority over decisions at work Coping wheel, ISSI and demands, control and support Q Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in ‘authority over decisions at work’ score (p=0.39)
Social support at work Coping wheel, ISSI and demands, control and support Q Follow-up3See commentSee commentNot estimable30
(1 study)
⊕⊝⊝⊝
Very low1,2
The results indicate no significant difference between groups in ‘social support at work’ score (p=0.68)

CI: confidence interval; GnRH: gonadotrophin releasing hormone; ISSI: Inventory of Social Support and Interaction; Q: questionnaire

1

The quality of the evidence was downgraded of 2 points because of the high risk of reporting bias (i.e. not Possible to access imprecision as only descriptive data with p values reported) and the potential risk of detection Bias (no details were given about randomisation and allocation concealment methods).

2

Only descriptive data reported, insufficient details given to assess the minimally important difference threshold and the imprecision

3

Follow-up at 6 months (at the end of the treatment period) and 12 months (6 months after the end of the treatment period) using analysis of variance (ANOVA) for repeated measures (mixed model)

From: 11, Management strategies

Cover of Endometriosis: diagnosis and management
Endometriosis: diagnosis and management.
NICE Guideline, No. 73.
National Guideline Alliance (UK).
© NICE 2017.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.